Zurich (awp) – The holding company BB Biotech was unable to repeat in the second quarter the performance recorded last year, plunging into the red. Between April and the end of June, the group specializing in investment in the biotechnology field suffered a net loss of 233 million Swiss francs, against a profit of 129 million Swiss francs during the corresponding partial of 2021.
The published loss corresponds to the performance of the securities in the portfolio, the Schaffhausen company said on Friday. Pre-tax profit was also in the red, with a loss of 233.05 million Swiss francs, compared with a profit of 128.6 million a year earlier. Revenues tumbled to 60 million, compared to 144.3 million in the second half of last year.
In the first half, BB Biotech, which is notably involved in the Moderna laboratory, known for having developed one of the anti-Covid-19 vaccines, suffered a net loss of 532.9 million Swiss francs, against a profit of 349 million a year earlier.
vj/al